{"schema_version":"secwatch.filing_event.v1","accession":"0001837607-26-000043","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2026-05-14T20:10:16+00:00","discovered_at":"2026-05-14T20:12:00.282237+00:00","generated_at":"2026-05-14T20:56:31.964930+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"low","headline":"AEON Biopharma posts corporate presentation targeting $3.5B neurotoxin market","bullets":["Corporate presentation made available on IR website, dated May 2026.","Presentation states AEON aims to disrupt a $3.5B neurotoxin market dominated by a single brand for over 30 years.","No specific financial results, clinical updates, or guidance changes disclosed in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001837607-26-000043","json":"https://secwatch.observer/filing/0001837607-26-000043.json","markdown":"https://secwatch.observer/filing/0001837607-26-000043.md","text":"https://secwatch.observer/filing/0001837607-26-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000183760726000043/0001837607-26-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000183760726000043/aeon-20260514x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T20:56:31.964930+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}